

## Special Issue

# African Swine Fever Virus Immunotherapies and Vaccine Development

### Message from the Guest Editors

ASFV affects both domestic pigs and wild boars, resulting in a significant economic impact on the global swine industry. Currently, there are no safe and effective vaccines or treatments for ASFV. Recent outbreaks have renewed the urgency to develop effective immunotherapies and vaccines to prevent and control ASFV. This Special Issue discusses recent advancements, innovative strategies, and ongoing research in ASFV immunology, vaccine development, and therapeutic interventions. Specifically, it will explore the immunological mechanisms involved in ASFV infection, candidate vaccines, therapeutic strategies, and diagnostic tools. We encourage submissions that address both the fundamental and applied aspects of ASFV immunology, offering new insights into potential solutions for combating this disease. We welcome original research articles and reviews in this Special Issue. Typical research areas may include:

- Immunology and vaccine development
- ASFV pathogenesis and immune evasion
- Vaccine candidates and development of vaccine strategies
- Diagnostics and technologies for ASFV
- Challenges and future directions in ASFV vaccine development

### Guest Editors

Prof. Dr. Tao Feng

State Key Laboratory for Animal Disease Control and Prevention,  
College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary  
Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou  
730046, China

Dr. Xiaodong Qin

State Key Laboratory of Veterinary Etiological Biology, Lanzhou  
Veterinary Research Institute, Chinese Academy of Agricultural  
Sciences, Lanzhou 730046, China

### Deadline for manuscript submissions

1 March 2026



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/231086](https://mdpi.com/si/231086)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).